Women of child-bearing potential, who are biologically able to conceive, not employing two forms of highly effective contraception or who are pregnant. 
Women who are breast-feeding 
Fertile males unwilling to use contraception 
Patients with brain metastases or any history of brain metastases 
Patients who have undergone major surgery (e.g., intra-thoracic, -abdominal, or -pelvic) </= 4 weeks prior to starting study treatment or who have not recovered from such therapy 
Patients with a history of pulmonary embolism, or untreated deep vein thrombosis within the past 6 months 
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of dovitinib 
The subject has had another active malignancy within the past 5 years except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin. 
Patients who have received the last administration of an anticancer therapy including chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies </= 2 weeks prior to starting the study drug, or who have not recovered from the side effects of such therapy 
Cirrhosis, chronic active hepatitis or chronic persistent hepatitis 
Patients who are currently receiving prasugrel 
No concurrent use of isoniazid, labetolol, trovafloxacin, tolcapone, and felbamate 
No concurrent use of other investigational drugs or antineoplastic therapies. 
Patients with impaired cardiac function or clinically significant cardiac diseases.       
    

NCT01888965_exc_T1
Person
Women
NCT01888965_exc_T2
Condition
child-bearing potential
NCT01888965_exc_T3
Condition
biologically able to conceive
NCT01888965_exc_T4
Multiplier
two
NCT01888965_exc_T5
Device
highly effective contraception
NCT01888965_exc_T6
Condition
pregnant
NCT01888965_exc_T7
Negation
not
NCT01888965_exc_T8
Scope
Women of child-bearing potential, who are biologically able to conceive
NCT01888965_exc_T9
Scope
not employing two forms of highly effective contraception or who are pregnant
NCT01888965_exc_T10
Person
Women
NCT01888965_exc_T11
Condition
breast-feeding
NCT01888965_exc_T12
Person
males
NCT01888965_exc_T13
Condition
Fertile
NCT01888965_exc_T14
Observation
unwilling to use contraception
NCT01888965_exc_T17
Condition
brain metastases
NCT01888965_exc_T18
Condition
brain metastases
NCT01888965_exc_T19
Observation
history
NCT01888965_exc_T20
Procedure
major surgery
NCT01888965_exc_T21
Procedure
intra-thoracic
NCT01888965_exc_T22
Procedure
intra -abdominal
NCT01888965_exc_T23
Procedure
intra -pelvic
NCT01888965_exc_T24
Scope
intra-thoracic, -abdominal, or -pelvic
NCT01888965_exc_T26
Value
</= 4 weeks prior to starting study treatment
NCT01888965_exc_T27
Reference_point
starting study treatment
NCT01888965_exc_T30
Condition
pulmonary embolism
NCT01888965_exc_T31
Condition
deep vein thrombosis
NCT01888965_exc_T32
Qualifier
untreated
NCT01888965_exc_T33
Temporal
within the past 6 months
NCT01888965_exc_T34
Observation
history
NCT01888965_exc_T35
Scope
pulmonary embolism, or untreated deep vein thrombosis
NCT01888965_exc_T36
Condition
Impairment of gastrointestinal (GI) function
NCT01888965_exc_T37
Condition
GI disease
NCT01888965_exc_T38
Qualifier
may significantly alter the absorption of dovitinib
NCT01888965_exc_T40
Scope
Impairment of gastrointestinal (GI) function or GI disease
NCT01888965_exc_T41
Condition
active malignancy
NCT01888965_exc_T42
Temporal
within the past 5 years
NCT01888965_exc_T43
Condition
cervical cancer in situ
NCT01888965_exc_T44
Negation
except
NCT01888965_exc_T45
Condition
in situ carcinoma of the bladder
NCT01888965_exc_T46
Condition
non-melanoma carcinoma of the skin
NCT01888965_exc_T47
Scope
cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin
NCT01888965_exc_T48
Procedure
anticancer therapy
NCT01888965_exc_T49
Procedure
chemotherapy
NCT01888965_exc_T50
Procedure
immunotherapy
NCT01888965_exc_T51
Procedure
hormonal therapy
NCT01888965_exc_T52
Drug
monoclonal antibodies
NCT01888965_exc_T53
Temporal
</= 2 weeks prior to starting the study drug
NCT01888965_exc_T54
Reference_point
starting the study drug
NCT01888965_exc_T55
Condition
recovered from the side effects of such therapy
NCT01888965_exc_T56
Negation
not
NCT01888965_exc_T57
Condition
recovered from such therapy
NCT01888965_exc_T58
Scope
chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies
NCT01888965_exc_T59
Condition
Cirrhosis
NCT01888965_exc_T60
Condition
chronic active hepatitis
NCT01888965_exc_T61
Condition
chronic persistent hepatitis
NCT01888965_exc_T62
Drug
prasugrel
NCT01888965_exc_T63
Drug
isoniazid
NCT01888965_exc_T64
Drug
labetolol
NCT01888965_exc_T65
Drug
trovafloxacin
NCT01888965_exc_T66
Drug
tolcapone
NCT01888965_exc_T67
Drug
felbamate
NCT01888965_exc_T68
Negation
No
NCT01888965_exc_T69
Scope
isoniazid, labetolol, trovafloxacin, tolcapone, and felbamate
NCT01888965_exc_T70
Negation
No
NCT01888965_exc_T71
Drug
other investigational drugs
NCT01888965_exc_T72
Procedure
antineoplastic therapies
NCT01888965_exc_T74
Scope
other investigational drugs or antineoplastic therapies
NCT01888965_exc_T75
Condition
impaired cardiac function
NCT01888965_exc_T76
Qualifier
clinically significant
NCT01888965_exc_T77
Condition
cardiac diseases